Furamidine
Based on 4 publication(s) in Google Scholar
Furamidine (DB75) is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 9.4 μM. Furamidine is selective for PRMT1 over PRMT5, PRMT6, and PRMT4 (CARM1) (IC50s of 166 µM, 283 µM, and >400 µM, respectively). Furamidine is a potent, reversible and competitive tyrosyl-DNA phosphodiesterase 1 (TDP-1) inhibitor. Inhibition of TDP-1 by Furamidine is effective both with single- and double-stranded DNA substrates but is slightly stronger with the duplex DNA. Furamidine is also an antiparasite agent.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 73819-26-8
- Formule: C18H16N4O
- Masse moléculaire:304.35
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Furamidine
MoreVoir tous les produits spécifiques à Isoform Histone Methyltransferase
MoreVoir tous les produits spécifiques à Isoform Parasite
More
Activité biologique
IC50: 9.4 μM (Protein arginine methyltransferase 1 (PRMT1)); 166 µM (PRMT5), 283 µM (PRMT6) and >400 µM (PRMT4)[1]
Parasite[1]
Tyrosyl-DNA phosphodiesterase 1 (TDP-1)[2]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
15.5 μM
Compound: 2
|
The compound was tested for cytotoxic potency against A2780R human tumor cell lines.
The compound was tested for cytotoxic potency against A2780R human tumor cell lines.
|
10.1016/S0960-894X(97)00229-1 |
| A2780 | IC50 |
46 μM
Compound: 2
|
The compound was tested for cytotoxic potency against A2780 human tumor cell lines
The compound was tested for cytotoxic potency against A2780 human tumor cell lines
|
10.1016/S0960-894X(97)00229-1 |
| B16 | IC50 |
9.2 μM
Compound: DB75
|
Drug concentration required to inhibit B16 cell growth by 50% after 72 hours of incubation
Drug concentration required to inhibit B16 cell growth by 50% after 72 hours of incubation
|
[PMID: 11985467] |
| CH1 | IC50 |
46.5 μM
Compound: 2
|
The compound was tested for cytotoxic potency against CH1 human tumor cell lines.
The compound was tested for cytotoxic potency against CH1 human tumor cell lines.
|
10.1016/S0960-894X(97)00229-1 |
| HEK293 | IC50 |
178.04 μM
Compound: 7e; DB75
|
Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 24 hrs by Alamar blue assay
Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 24 hrs by Alamar blue assay
|
[PMID: 28038325] |
| HEK-293T | IC50 |
166 μM
Compound: 1, DB75, furamidine
|
Inhibition of HA-tagged recombinant PRMT5 (unknown origin) expressed in HEK293T cells using [3H]SAM and histone H4 (1 to 20) as substrate after 8 mins by P81 filter binding assay
Inhibition of HA-tagged recombinant PRMT5 (unknown origin) expressed in HEK293T cells using [3H]SAM and histone H4 (1 to 20) as substrate after 8 mins by P81 filter binding assay
|
[PMID: 24564570] |
| L6 | IC50 |
16.4 μM
Compound: furamidine
|
Cytotoxicity against rat L6 cells
Cytotoxicity against rat L6 cells
|
[PMID: 17439202] |
| L6 | IC50 |
23.3 μM
Compound: FMD, DB75, Furamidine
|
Antiprotozoal activity against intracellular amastigote form of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ infected in rat L6 cells after 48 hrs
Antiprotozoal activity against intracellular amastigote form of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ infected in rat L6 cells after 48 hrs
|
[PMID: 23795673] |
| L6 | IC50 |
6.4 mM
Compound: FMD
|
Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay
Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay
|
[PMID: 23871911] |
| L6 | IC50 |
6.4 nM
Compound: Furamidine
|
Cytotoxicity against rat L6 cells by alamar blue assay
Cytotoxicity against rat L6 cells by alamar blue assay
|
[PMID: 17178177] |
| L6 | IC50 |
6.4 μM
Compound: 2
|
Cytotoxicity against rat L6 cells
Cytotoxicity against rat L6 cells
|
[PMID: 16913722] |
| L6 | IC50 |
6.4 μM
Compound: FMD
|
Cytotoxicity against rat L6 cells
Cytotoxicity against rat L6 cells
|
[PMID: 19409677] |
| L6 | IC50 |
6.4 μM
Compound: FMD
|
Cytotoxicity against rat L6 cells by Alamar blue assay
Cytotoxicity against rat L6 cells by Alamar blue assay
|
[PMID: 34146914] |
| L6 | IC50 |
6.4 μM
Compound: FMD, DB75, Furamidine
|
Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay
Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay
|
[PMID: 23795673] |
| L6 | IC50 |
6.4 μM
Compound: FMD, Furamidine
|
Cytotoxicity against rat L6 cells assessed as cell viability after 70 hrs by Alamar blue assay
Cytotoxicity against rat L6 cells assessed as cell viability after 70 hrs by Alamar blue assay
|
[PMID: 24268543] |
| L6 | IC50 |
6.4 μM
Compound: Furamidine
|
Cytotoxicity against rat L6 cells by alamar blue assay
Cytotoxicity against rat L6 cells by alamar blue assay
|
[PMID: 21194955] |
| L6 | IC50 |
6.4 μM
Compound: IIa
|
Cytotoxicity against rat L6 cells
Cytotoxicity against rat L6 cells
|
[PMID: 21421317] |
| L6 | IC50 |
6.5 μM
Compound: IIa
|
Cytotoxicity against rat L6 cells
Cytotoxicity against rat L6 cells
|
[PMID: 20403703] |
| L6 | IC50 |
6.7 μM
Compound: Furamidine
|
Cytotoxicity against rat L6 cells
Cytotoxicity against rat L6 cells
|
[PMID: 20031421] |
| L6 | IC50 |
6.7 μM
Compound: Table 1, R1C1
|
Cytotoxicity against rat L6 cells assessed as reduction in cell viability incubated for 70 hrs by Alamar blue based microplate fluorescence assay
Cytotoxicity against rat L6 cells assessed as reduction in cell viability incubated for 70 hrs by Alamar blue based microplate fluorescence assay
|
[PMID: 36958267] |
| L6 | IC50 |
6400 nM
Compound: 2a
|
Cytotoxicity against rat L6 cells
Cytotoxicity against rat L6 cells
|
[PMID: 19699098] |
| L6 | IC50 |
6400 nM
Compound: 2a
|
Cytotoxicity against rat L6 cells assessed as cell viability after 70 hrs by Alamar blue assay
Cytotoxicity against rat L6 cells assessed as cell viability after 70 hrs by Alamar blue assay
|
[PMID: 24012380] |
| L6 | IC50 |
6400 μM
Compound: IIa, furamidine
|
Cytotoxicity against rat L6 cells
Cytotoxicity against rat L6 cells
|
[PMID: 17976993] |
| SK-OV-3 | IC50 |
42.5 μM
Compound: 2
|
The compound was tested for cytotoxic potency against SKOV-3 human tumor cell lines.
The compound was tested for cytotoxic potency against SKOV-3 human tumor cell lines.
|
10.1016/S0960-894X(97)00229-1 |
Furamidine (compound 1; 20 μM; 72 hours; leukemia cell lines) inhibits cell growth for most of the leukemia cell lines except HEL cells which have JAK2V617F mutations[1].
Furamidine (compound 1; 20 μM; 15 hours; 293T cells) treatment significantly reduces the expression level of the methylated GFP-ALY protein in 293T cells[1].
Furamidine binds duplex DNA in the DNA minor groove selectively at AT rich sites [(A/T)4]. Furamidine can also intercalate between GC base pairs of duplex DNA. Furamidine could therefore interfere with DNA processing enzymes such as TDP-1[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Meg-01, K562, HL-60, NB4, MOLM13, HEL, CMK, CMY, CMS and CHRF cells
-
Concentration:20 μM
-
Incubation Time:72 hours
-
Result:Inhibited cell growth for most of the leukemia cell lines except HEL cells which have JAK2V617F mutations.
-
Cell Line:293T cells
-
Concentration:20 μM
-
Incubation Time:15 hours
-
Result:The expression level of the methylated GFP-ALY protein is significantly reduced.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female NZB/NZW mice (6-week-old) with Irinotecan (1 mg/kg)[3]
-
Dosage:1 mg/kg
-
Administration:Intraperitoneal injection; 3 times a week and repeated every 4 weeks; for 34 weeks
-
Result:Suppressed proteinuria and prolongs survival of lupus-prone NZB/NZW mice combined with Irinotecan.
Chemical Information
-
CAS No. 73819-26-8
-
Masse moléculaire 304.35
-
Formule C18H16N4O
-
SMILES
N=C(C1=CC=C(C2=CC=C(C3=CC=C(C(N)=N)C=C3)O2)C=C1)N
-
Synonyms
DB75; NSC 305831
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Antioxidants (Basel)
A Novel SIRT1 Activator Hydroxygenkwanin Alleviates Osteoporosis by Inhibiting Ferroptosis and Lactylation in Skeletal Stem/Progenitor Cells. [Abstract]2026 May 12;15(5):612. PMID: 42193234 -
Cell Rep
CRISPR screening identifies PRMT1 as a key pro-ferroptotic gene via a two-layer regulatory mechanism. [Abstract]2024 Aug 22;43(9):114662. PMID: 39178116 -
Int Immunopharmacol
DB75 targets PRMT1 to suppress liver metastasis and synergizes with PD-L1 blockade for enhanced therapeutic efficacy. [Abstract]2025 Aug 8:164:115327. PMID: 40782428 -
Pureté et documentation
Références
[1]. Yan L, et al. Diamidine compounds for selective inhibition of protein arginine methyltransferase 1. J Med Chem. 2014 Mar 27;57(6):2611-22. [Content Brief]
[2]. Antony S, et al. Novel high-throughput electrochemiluminescent assay for identification of human tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1. Nucleic Acids Res. 2007;35(13):4474-8 [Content Brief]
[3]. Keil A, et al. The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis. Arthritis Rheumatol. 2015 Jul;67(7):1858-67. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)